Stockscreener 앱 받기
50.08
4.48%
-2.35
전일 마감가:
$52.43
열려 있는:
$52
하루 거래량:
2.31M
Relative Volume:
1.24
시가총액:
$4.72B
수익:
$536.20M
순이익/손실:
$-45.64M
주가수익비율:
-93.64
EPS:
-0.5348
순현금흐름:
$-28.94M
1주 성능:
+0.97%
1개월 성능:
-16.30%
6개월 성능:
+22.68%
1년 성능:
+77.90%
1일 변동 폭
$49.78
$52.22
1주일 범위
$49.74
$54.83
52주 변동 폭
$22.59
$68.73
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
50.08 | 4.72B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research
The CEO exercises options at $8.93 and sells shares in Travere Therapeutics (TVTX). - Stock Titan
An officer proposes selling 243,735 shares at Travere Therapeutics (TVTX). - Stock Titan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com India
Travere Therapeutics Insider Sold Shares Worth $2,337,695, According to a Recent SEC Filing - Yahoo Finance
Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing - Yahoo Finance
Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing - Yahoo Finance
Travere therapeutics chief research officer William Rote sells $13.1m in stock - Investing.com Nigeria
Travere Therapeutics CLO Elizabeth Reed sells $2.34m in stock By Investing.com - Investing.com Nigeria
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com
Travere Therapeutics CFO Cline sells $3.1m in company stock - Investing.com
Travere Therapeutics SVP sells $335k in stock - Investing.com
Travere Therapeutics SVP sells $335k in stock By Investing.com - Investing.com Canada
Travere (TVTX) R&D boss sells stock under 10b5-1 plan—how big was the trade? - Stock Titan
Insider at Travere (NASDAQ: TVTX) sells stock under preset trading plan - Stock Titan
Travere Therapeutics (TVTX) legal chief sells 37,500 shares under trading plan - Stock Titan
Travere CFO (NASDAQ: TVTX) sells 50K shares in pre-set trading plan - Stock Titan
Travere Therapeutics (TVTX) CEO trades 400K shares under preset plan - Stock Titan
Travere Therapeutics (TVTX) research chief unloads shares under a preset plan, with the sale size now disclosed - Stock Titan
Planned $6.9M stock sale in Travere (NASDAQ: TVTX) - Stock Titan
Travere Therapeutics, Inc.Common Stock (Nasdaq:TVTX) Price Chart - The Chronicle-Journal
Travere Therapeutics (TVTX) chief accounting officer sells 5,375 shares under preset plan - Stock Titan
Travere (NASDAQ: TVTX) insider plans more stock sales after multi-million plan trades - Stock Titan
Travere Therapeutics CFO Cline sells $3.1m in company stock By Investing.com - Investing.com Canada
Travere therapeutics chief research officer William Rote sells $13.1m in stock - Investing.com
Travere Therapeutics (NASDAQ: TVTX) officer plans 112,850-share sale after recent 96,198-share trade - Stock Titan
After $6M sale, Travere (NASDAQ: TVTX) insider plans another stock move - Stock Titan
Travere Therapeutics (TVTX) insider plans 172,717-share sale after option exercise - Stock Titan
Insider plans 39,576-share sale at Travere Therapeutics (NASDAQ: TVTX) in 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) shareholder Eric Dube plans 95,666-share sale in September 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer may sell shares after cashing in options - Stock Titan
$2.9M planned stock sale at Travere (NASDAQ: TVTX) comes from equity awards - Stock Titan
Over 100,000 Travere (NASDAQ: TVTX) shares lined up for insider sale - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer plans Rule 144 sale of compensation shares - Stock Titan
TVTX Form 4 FilingsTravere Therapeutics, Inc. SEC Form 4 - Stock Titan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Director at Travere Therapeutics (TVTX) sells 20,000 shares under preset trading plan - Stock Titan
Show Me The Money: Filspari Powers Travere Therapeutics' Growth - RTTNews
Travere Therapeutics grants inducement RSUs covering 56,220 shares to 16 new employees - Bitget
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Australia
Travere Therapeutics (NASDAQ: TVTX) director plans 2026 stock sale - Stock Titan
TVTX: FILSPARI's momentum and pipeline progress position the business for sustained growth - TradingView
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com Canada
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com UK
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Travere Therapeutics Inc 주식 (TVTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ERIC DUBE | Director |
Oct 15 '26 |
Proposed Sale |
53.27 |
243,735 |
12,983,763 |
0 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Oct 15 '26 |
Sale |
53.82 |
243,735 |
13,116,671 |
432,886 |
| ERIC DUBE | Director |
Sep 17 '26 |
Proposed Sale |
63.48 |
108,493 |
6,887,136 |
0 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 17 '26 |
Option Exercise |
22.40 |
8,282 |
185,517 |
125,348 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 17 '26 |
Option Exercise |
23.34 |
108,493 |
2,532,227 |
541,379 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 17 '26 |
Sale |
64.61 |
108,493 |
7,009,671 |
432,886 |
| PETER HEERMA | Officer |
Sep 17 '26 |
Proposed Sale |
63.48 |
8,282 |
525,741 |
0 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 17 '26 |
Sale |
65.07 |
8,282 |
538,917 |
117,066 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 16 '26 |
Option Exercise |
23.34 |
195,841 |
4,570,929 |
628,727 |
| ERIC DUBE | Director |
Sep 16 '26 |
Proposed Sale |
62.51 |
195,841 |
12,242,021 |
0 |
1.20%
2.49%
자본화:
|
볼륨(24시간):